<span item_type="fundamental" item_id="801c4478295cf1972b2c0bdf31467d57" counter_id="ST/US/AIMDW" env="prod"></span><span item_type="announcement" item_id="582437203512136833" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 2.167 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.64.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.608 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Revenue for the three months ended September 30, 2025 was $2,167, compared to $0 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li><li>Revenue for the nine months ended September 30, 2025 was $113,037, compared to $20,729 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net loss for the three months ended September 30, 2025 was - $2,931,702, compared to - $3,699,317 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li><li>Net loss for the nine months ended September 30, 2025 was - $10,302,714, compared to - $10,209,149 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li><li>Gross profit for the three months ended September 30, 2025 was $1,690, compared to a gross loss of - $547 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li><li>Gross profit for the nine months ended September 30, 2025 was $93,390, compared to a gross loss of - $31,945 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the nine months ended September 30, 2025 was - $3,759,679, compared to - $4,944,036 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li><li>Net cash used in investing activities for the nine months ended September 30, 2025 was - $13,112, compared to - $138,577 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li><li>Net cash provided by financing activities for the nine months ended September 30, 2025 was $852,635, compared to $8,295,746 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>R&amp;D expenses decreased to $5,626,514 for the nine months ended September 30, 2025, compared to $6,085,648 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li><li>SG&amp;A expenses increased to $4,159,627 for the nine months ended September 30, 2025, compared to $3,090,056 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company plans to scale the AI Nose platform in industrial, robotics, and long-term care settings, supported by a subscription-based model offering AI-driven scent analytics and hardware services.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li><li>The company is advancing select VELDONA programs through cost-effective clinical studies in Taiwan, balancing development progress with capital discipline and exploring potential licensing or partnership opportunities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li><li>The company anticipates business revenues and external financing options to fund operations over the next twelve months, but acknowledges the need for additional capital to finance continuing operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1014763/000149315225022312/form10-q.htm"></span></li></ul>

AINOS INC C/WTS 29/07/2027 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 2.167 K